NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NSPR

InspireMD Inc

Jul 01 • 04:00PM ET

2.23

Dollar change -0.04
Percentage change -1.76	%

Healthcare • Medical Devices • USA • NASD

Peers: ABT MDT BSX EW SYK ISRG HOLX ZBH AORT NVRO

| Held by: IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.79	Insider Own	36.24%	Shs Outstand	29.75M	Perf Week	-9.90%
Market Cap	68.32M	Forward P/E	-	EPS next Y	-0.91	Insider Trans	0.00%	Shs Float	19.53M	Perf Month	-12.89%
Enterprise Value	44.55M	PEG	-	EPS next Q	-0.26	Inst Own	36.30%	Short Float	1.00%	Perf Quarter	-17.10%
Income	-36.14M	P/S	9.72	EPS this Y	-30.52%	Inst Trans	3.05%	Short Ratio	1.34	Perf Half Y	-22.30%
Sales	7.03M	P/B	2.34	EPS next Y	9.45%	ROA	-89.56%	Short Interest	0.20M	Perf YTD	-15.21%
Book/sh	0.95	P/C	2.62	EPS next 5Y	18.29%	ROE	-113.95%	52W High	3.80 -41.28%	Perf Year	-10.80%
Cash/sh	0.85	P/FCF	-	EPS past 3/5Y	27.83% 59.73%	ROIC	-120.53%	52W Low	1.99 12.06%	Perf 3Y	9.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	15.96% 13.50%	Gross Margin	21.43%	Volatility	8.27% 5.96%	Perf 5Y	-70.28%
Dividend TTM	-	EV/Sales	6.34	EPS Y/Y TTM	6.09%	Oper. Margin	-534.35%	ATR (14)	0.16	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	3.98	Sales Y/Y TTM	8.49%	Profit Margin	-514.29%	RSI (14)	39.09	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.36	EPS Q/Q	-8.76%	SMA20	-7.63%	Beta	0.59	Target Price	4.50
Payout	-	Debt/Eq	0.08	Sales Q/Q	1.19%	SMA50	-9.26%	Rel Volume	0.48	Prev Close	2.27
Employees	86	LT Debt/Eq	0.06	Earnings	May 09 BMO	SMA200	-16.45%	Avg Volume	146.37K	Price	2.23
IPO	Apr 11, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.00% 5.30%	Trades		Volume	71,802	Change	-1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-16	Initiated	Rodman & Renshaw	Buy	$4
Mar-13-15	Downgrade	Oppenheimer	Outperform → Perform
Nov-26-13	Initiated	Oppenheimer	Outperform	$6

Jun-24-25 04:05PM	InspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of Stroke (GlobeNewswire) -9.49%
Jun-13-25 09:00AM	InspireMD Announces CE Mark Approval for CGuard Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke (GlobeNewswire) -7.20%
Jun-03-25 04:05PM	InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer (GlobeNewswire)
May-10-25 03:04AM	InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges (GuruFocus.com)
May-09-25 08:15AM	InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	InspireMD Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-08-25 05:45PM	Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates (Zacks)
09:49AM	InspireMD Inc (NSPR) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-06-25 08:10AM	IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 09:00AM	InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference (GlobeNewswire)
Apr-25-25 09:00AM	InspireMD to Announce First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 09:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-25 09:00AM	InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-13-25 03:04AM	InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ... (GuruFocus.com)
Mar-12-25 07:00AM	InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
08:00AM	Loading…
Feb-26-25 08:00AM	InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 08:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.11%
Feb-13-25 07:00AM	InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime 80 cm Carotid Stent System for Use in TCAR procedures (GlobeNewswire)
Feb-04-25 07:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.20%
Jan-21-25 07:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.92%
Dec-12-24 07:00AM	InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 (GlobeNewswire)
Dec-09-24 07:00AM	InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) (GlobeNewswire)
Nov-25-24 04:05PM	InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors (GlobeNewswire) +10.94%
Nov-13-24 02:09AM	InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ... (GuruFocus.com) +5.24%
Nov-12-24 07:00AM	InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:25AM	What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings (GuruFocus.com) +7.68%
Nov-08-24 05:30PM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-24 08:00AM	InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th (GlobeNewswire)
Oct-15-24 07:00AM	InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System (GlobeNewswire) -5.66%
Oct-08-24 07:28AM	InspireMD Advances with FDA Study Approval and Global Goals (TipRanks)
07:00AM	Loading…
Oct-07-24 07:00AM	InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System (GlobeNewswire)
Sep-16-24 07:00AM	InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System (GlobeNewswire)
Aug-06-24 08:09AM	InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:00AM	InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment (GlobeNewswire)
Jul-30-24 07:00AM	InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th (GlobeNewswire) -16.87%
Jul-01-24 07:00AM	InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million (GlobeNewswire)
May-28-24 08:53AM	InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 (GlobeNewswire)
May-14-24 10:53AM	NSPR Stock Earnings: InspireMD Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th (GlobeNewswire)
Apr-03-24 08:59AM	InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:00AM	InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 (GlobeNewswire)
Mar-07-24 10:09AM	InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:53PM	NSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:00AM	InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th (GlobeNewswire)
Feb-12-24 07:00AM	InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System (GlobeNewswire)
Feb-05-24 11:27AM	InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS (Zacks)
Jan-31-24 07:00AM	InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework (GlobeNewswire)
Jan-03-24 07:00AM	InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America (GlobeNewswire)
Dec-20-23 07:00AM	InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System (GlobeNewswire) -5.50%
Nov-27-23 07:00AM	InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions (GlobeNewswire) +6.41%
Nov-07-23 09:12AM	InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:11AM	InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ... (GuruFocus.com)
07:00AM	InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-23 08:00AM	InspireMD to Participate in Upcoming November Investor Conferences (GlobeNewswire) -11.41%
Nov-01-23 02:19PM	InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 (GlobeNewswire) +11.21%
Oct-30-23 09:21AM	InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th (GlobeNewswire) -7.12%
Oct-12-23 07:00AM	InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients (GlobeNewswire) +12.50%
Oct-03-23 07:00AM	InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives (GlobeNewswire)
Aug-31-23 08:00AM	InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 (GlobeNewswire) +5.37%
Aug-08-23 07:00AM	InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-23 08:00AM	InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th (GlobeNewswire)
Jun-26-23 08:00AM	InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial (GlobeNewswire) +7.01%
May-18-23 08:00AM	InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-23 07:00AM	InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.70%
May-15-23 08:00AM	InspireMD Announces Private Placement of Up to $113.6 Million (GlobeNewswire) +26.90%
May-12-23 04:05PM	InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast (GlobeNewswire)
May-05-23 08:00AM	InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update (GlobeNewswire)
May-01-23 08:00AM	InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform (GlobeNewswire) +44.23%
Apr-27-23 08:00AM	InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update (GlobeNewswire)
Mar-30-23 07:00AM	InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update (GlobeNewswire) -7.83%
Mar-20-23 08:00AM	InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer (GlobeNewswire)
Mar-02-23 08:00AM	InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update (GlobeNewswire)
Feb-14-23 08:00AM	InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing (GlobeNewswire) +6.23%
Nov-28-22 08:00AM	InspireMD Announces 12 Days of Carotid Stenting Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists (GlobeNewswire)
Nov-15-22 04:05PM	InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium (GlobeNewswire) +6.87%
Nov-08-22 07:00AM	InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -14.81%
Oct-25-22 08:00AM	InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update (GlobeNewswire)
Sep-13-22 04:05PM	InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference (GlobeNewswire)
Sep-08-22 09:00AM	NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development (Business Wire)
Aug-09-22 07:00AM	InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -5.91%
Aug-02-22 08:00AM	InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update (GlobeNewswire)
Jul-14-22 08:00AM	InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor (GlobeNewswire)
Jun-09-22 08:00AM	InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022 (GlobeNewswire)
Jun-02-22 08:00AM	InspireMDs CGuard Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022 (GlobeNewswire)
May-10-22 07:30AM	InspireMD Reports First Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Apr-28-22 07:30AM	InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update (GlobeNewswire)
Mar-16-22 04:05PM	InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard Stent Platform & MicroNet Portfolio (GlobeNewswire) +8.08%
Mar-08-22 07:30AM	InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results (GlobeNewswire)
Feb-28-22 07:00AM	InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application (GlobeNewswire)
Feb-22-22 04:30PM	InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update (GlobeNewswire)
Feb-15-22 08:00AM	InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor (GlobeNewswire)
Jan-27-22 08:00AM	InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS) (GlobeNewswire)
Jan-18-22 08:11AM	InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial (GlobeNewswire)
Nov-22-21 06:02AM	We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate (Simply Wall St.)
Nov-09-21 07:30AM	InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-21 04:05PM	InspireMD Announces Publication of 12-Month Results of CGuard EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions (GlobeNewswire)
Oct-26-21 08:30AM	InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update (GlobeNewswire)
Oct-13-21 08:30AM	InspireMD Receives Reimbursement Approval for CGuard Embolic Prevention System from the French National Authority for Health (GlobeNewswire) +5.10%

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NSPR

InspireMD Inc

Upgrade your FINVIZ experience